Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

21. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors (PubMed)

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors Anticoagulants such as unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), fondaparinux, and direct oral anticoagulants (DOACs) targeting thrombin (IIa) or factor Xa (FXa) are widely used in prevention and treatment of thromboembolic disorders. However, anticoagulant-associated bleeding is a concern that demands monitoring and neutralization. Protamine (...) , the UFH antidote, has limitations, while there is no antidote available for certain direct FXa inhibitors. Improved antidotes in development include UHRA (Universal Heparin Reversal Agent) for all heparin anticoagulants; andexanet alfa (andexanet), a recombinant antidote for both direct FXa inhibitors and LMWHs; and ciraparantag (PER977), a small-molecule antidote for UFH, LMWHs, and certain DOACs. The binding affinities of these antidotes for their presumed anticoagulant targets have not been

Full Text available with Trip Pro

2018 Blood advances

22. Heparin

Heparin Top results for heparin - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for heparin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

23. Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults. (PubMed)

Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults. Intermittent locking of central venous catheters (CVCs) is undertaken to help maintain their patency. There are systematic variations in care: some practitioners use heparin (at different concentrations), whilst others use 0.9% NaCl (normal saline). This review looks at the effectiveness and safety of intermittent locking with heparin compared to 0.9% NaCl to see if the evidence (...) establishes whether one is better than the other. This work is an update of a review first published in 2014.To assess the effectiveness and safety of intermittent locking of CVCs with heparin versus normal saline (NS) in adults to prevent occlusion.The Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (last searched 11 June 2018) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 5). Searches were also carried out in MEDLINE, Embase, CINAHL

2018 Cochrane

24. Heparin Oligosaccharides Have Antiarrhythmic Effect by Accelerating the Sodium-Calcium Exchanger (PubMed)

Heparin Oligosaccharides Have Antiarrhythmic Effect by Accelerating the Sodium-Calcium Exchanger Background: Blockage of the Na+/Ca2+ exchanger (NCX) is used to determine the role of NCX in arrhythmogenesis. Trisulfated heparin disaccharide (TD) and Low Molecular Weight Heparins (LMWHs) can directly interact with the NCX and accelerate its activity. Objective: In this work, we investigated the antiarrhythmic effect of heparin oligosaccharides related to the NCX activity. Methods: The effects (...) of heparin oligosaccharides were tested on the NCX current (patch clamping) and intracellular calcium transient in rat cardiomyocytes. The effects of heparin oligosaccharides were further investigated in arrhythmia induced in isolated rat atria and rats in vivo. Results: The intracellular Ca2+ concentration decreases upon treatment with either enoxaparin or ardeparin. These drugs abolished arrhythmia induction in isolated atria. The NCX antagonist KB-R7943 abolished the enoxaparin or ardeparin

Full Text available with Trip Pro

2018 Frontiers in cardiovascular medicine

25. Heparin-induced thrombocytopenia: A critical appraisal of clinical practice guidelines with the AGREE II instrument

Heparin-induced thrombocytopenia: A critical appraisal of clinical practice guidelines with the AGREE II instrument Despite the availability of clinical practice guidelines (CPGs), the risk of death or thromboembolic complication associated with heparin-induced thrombocytopenia (HIT) remains high. Our aim was to systematically review the quality of CPGs for HIT and summarize the recommendations.CPGs for HIT were systematically searched on PubMed, Embase, guidelines' websites, and Google up (...) and clarity of presentation obtained the highest median scores, while the domain of rigor of development and editorial independence obtained the lowest median scores. The ACCP guideline and BSH guideline were recommended for use in dealing with HIT, achieving a score of at least 50% in all six AGREE II domains. Recommendations across guidelines were inconsistent, especially in the choice of non-heparin anticoagulant for HIT.Future HIT guidelines should place more emphasis on methodological quality

2018 EvidenceUpdates

26. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and ≤48 h anticoagulation prior to randomization undergoing cardioversion.One thousand five hundred patients were randomized. The apixaban dose of 5 mg b.i.d. was reduced to 2.5 mg b.i.d. in patients with two of the following: age ≥ 80 (...) , and 342 received a loading dose of apixaban. Comparing apixaban to heparin/VKA in the full analysis set, there were 0/753 vs. 6/747 strokes [relative risk (RR) 0; 95% confidence interval (95% CI) 0-0.64; nominal P = 0.015], no SE, and 2 vs. 1 deaths (RR 1.98; 95% CI 0.19-54.00; nominal P > 0.999). In the safety population, there were 3/735 vs. 6/721 major (RR 0.49; 95% CI 0.10-2.07; nominal P = 0.338) and 11 vs. 13 CRNM bleeding events (RR 0.83; 95% CI 0.34-1.89; nominal P = 0.685). On imaging, 60/61

Full Text available with Trip Pro

2018 EvidenceUpdates

27. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis

Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer-associated venous thromboembolism (VTE). We aim to synthesize existing literature that compared DOACs versus LMWHs in this high-risk population.We conducted a systematic review

2018 EvidenceUpdates

28. An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart

An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart Discover Portal Discover Portal An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart Published on 14 June 2016 doi: Bivalirudin is currently recommended as an alternative option to heparin to prevent (...) clotting during percutaneous coronary intervention. This is a common procedure to unblock the heart’s arteries. It is more costly but may have advantages relative to heparin, such as a more rapid action and less risk of lowering the platelet count. This review found that bivalirudin reduced risk of major bleeding compared with heparin. However, this was only when heparin was combined with a higher dose of another anti-clotting drug, a glycoprotein platelet IIb/IIIa inhibitor. When there was equivalent

2018 NIHR Dissemination Centre

29. 2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia (PubMed)

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia Thrombocytopenia is a significant complication of chemotherapy and radiation therapy. Platelet factor 4 (PF4; CXCL4) is a negative paracrine of megakaryopoiesis. We have shown that PF4 levels are inversely related to steady-state platelet counts, and to the duration and severity of chemotherapy- and radiation-induced thrombocytopenia (CIT and RIT, respectively). Murine studies suggest that blocking (...) the effect of PF4 improves megakaryopoiesis, raising nadir platelet counts and shortening the time to platelet count recovery. We examined the ability of 2-O, 3-O desulfated heparin (ODSH), a heparin variant with little anticoagulant effects, to neutralize PF4's effects on megakaryopoiesis. Using megakaryocyte colony assays and liquid cultures, we show that ODSH restored megakaryocyte proliferation in PF4-treated Cxcl4-/- murine and human CD34+-derived megakaryocyte cultures (17.4% megakaryocyte colonies

Full Text available with Trip Pro

2018 Blood advances

30. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia (PubMed)

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01

Full Text available with Trip Pro

2018 Blood advances

31. Heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia Heparin-induced thrombocytopenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Heparin-induced thrombocytopenia Last reviewed: February 2019 Last updated: May 2018 Summary A severe drug reaction to heparin that can lead to life- and limb-threatening venous and/or arterial thromboembolism. Diagnosis requires the combination of a compatible clinical picture and laboratory confirmation (...) of the presence of heparin-dependent platelet-activating HIT antibodies. Neither discontinuation of heparin alone nor initiation of a vitamin K antagonist alone (e.g., warfarin) is sufficient to stop the development of thrombosis in a patient with acute HIT. If clinical suspicion for HIT is at least moderate, all sources of heparin (including low molecular weight heparin) must be discontinued and initiation of treatment with a non-heparin anticoagulant considered. Definition Heparin-induced thrombocytopenia

2018 BMJ Best Practice

32. Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia:

Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: | CADTH.ca Find the information you need Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: Last updated: October 2, 2018 Project Number: RC1025-000 Product Line: Research Type (...) : Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines regarding the frequency of complete blood counts to monitor for heparin-induced thrombocytopenia during intravenous heparin infusions for cardiac conditions? Key Message No relevant evidence-based guidelines were identified regarding the frequency of complete blood counts to monitor for heparin-induced thrombocytopenia during intravenous heparin infusions for cardiac

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

33. Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study) (PubMed)

Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study) 29456608 2018 11 13 1751-1437 19 1 2018 Feb Journal of the Intensive Care Society J Intensive Care Soc Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study). 80-82 10.1177/1751143717737408 eng Journal Article Review 2017 11 28 England J Intensive Care Soc 101538668 1751-1437 2018 2 20 6 0 2018 2 20 6 0 2018 2 20 6 1 ppublish 29456608 10.1177/1751143717737408 10.1177_1751143717737408

Full Text available with Trip Pro

2017 Journal of the Intensive Care Society

34. Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines

Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Acetylsalicylic (...) Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Published on: November 14, 2017 Project Number: RC0941-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of acetylsalicylic acid versus low-molecular-weight heparin for venous thromboembolism prophylaxis in patients undergoing total hip or knee replacement? What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

35. Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. (PubMed)

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. Heparin is an anticoagulant medication that is usually injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma, and pain at the injection site. One of the factors that may affect pain, haematoma, and bruising is injection speed. For patients and healthcare providers, strategies that can reduce pain and bruising are considered (...) important. Reducing patients' discomfort and concerns whenever and wherever possible is an important aim of nursing. Several studies have been carried out to see if speed of injection affects the amount of pain and bruising where the injection is given, but results of these studies have differed and study authors have not reached a clear final conclusion. This is the first update of the review first published in 2014.To assess the effects of duration (speed) of subcutaneous heparin injection on pain

2017 Cochrane

36. Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. (PubMed)

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. Heparin is an anticoagulant medication that is usually injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma, and pain at the injection site. One of the factors that may affect pain, haematoma, and bruising is injection speed. For patients and healthcare providers, strategies that can reduce pain and bruising are considered (...) important. Reducing patients' discomfort and concerns whenever and wherever possible is an important aim of nursing. Several studies have been carried out to see if speed of injection affects the amount of pain and bruising where the injection is given, but results of these studies have differed and study authors have not reached a clear final conclusion. This is the first update of the review first published in 2014.To assess the effects of duration (speed) of subcutaneous heparin injection on pain

2017 Cochrane

37. Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines

Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin Lock Solutions for Open-Ended Vascular Access (...) Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Published on: September 13, 2017 Project Number: RA0929-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of heparin lock solutions to maintain the patency of open-ended central vascular access devices? What are the evidence-based guidelines associated with the use of heparin lock solutions to maintain the patency of open-ended central vascular

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

38. Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines

Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical (...) Effectiveness, Safety, and Guidelines Published on: September 7, 2017 Project Number: RA0928-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness and safety of heparin 5,000 u/0.5 mL for catheter lock or flush? What are the evidence-based guidelines associated with the use of heparin for catheter lock or flush? Key Message Two systematic reviews (both including meta-analyses) were identified regarding heparin (5,000 u/0.5 mL

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

39. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. (PubMed)

Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors.In this multicenter, randomized, registry (...) -based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors. The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access. The primary end point

2017 NEJM

40. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization. (PubMed)

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization. Immobilization of the lower limb is a risk factor for venous thromboembolism (VTE). Low molecular weight heparins (LMWHs) are anticoagulants, which might be used in adult patients with lower-limb immobilization to prevent deep venous thrombosis (DVT) and its complications. This is an update of the review first published in 2008.To assess the effectiveness of low molecular weight (...) heparin for the prevention of venous thromboembolism in patients with lower-limb immobilization in an ambulatory setting.For this update, the Cochrane Vascular Information Specialist searched the Specialised Register, CENTRAL, and three trials registers (April 2017).Randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that described thromboprophylaxis by means of LMWH compared with no prophylaxis or placebo in adult patients with lower-limb immobilization. Immobilization

Full Text available with Trip Pro

2017 Cochrane